This research provides insights into the role of the Th-22/IL-22 axis in COPD and evaluates the therapeutic potential of fezakinumab and AG490, offering hope for improved management of this chronic, intractable disease. This evidence concerns the gene IL22 and chronic obstructive pulmonary disease.